You are here

Article info

Article menu
Chronic obstructive pulmonary disease
Original article
Benefits and harms of roflumilast in moderate to severe COPD
Free

Authors

  1. Correspondence to Professor Milo Puhan, Institute of Social and Preventive Medicine, University of Zurich, Hirschengraben 84, Zurich CH-8001, Switzerland; milo.puhan{at}ifspm.uzh.ch
View Full Text

Citation

Yu T, Fain K, Boyd CM, et al
Benefits and harms of roflumilast in moderate to severe COPD
Thorax 2014;69:616-622.

Publication history

  • Received July 8, 2013
  • Revised November 18, 2013
  • Accepted December 4, 2013
  • First published December 17, 2013.
Online issue publication 
June 10, 2014

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

    Files in this Data Supplement:

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions